TSXV: ACB
VANCOUVER, March 9, 2017 /CNW/ - Aurora Cannabis Inc.
(the "Company" or "Aurora") (TSXV: ACB) (OTCQB: ACBFF)
(Frankfurt: 21P; WKN: A1C4WM) is
pleased to announce that it is introducing the cannabis industry's
most comprehensive product testing disclosure process. Today, the
Company completed the first step in a two-step process that will
provide Aurora clients and the general public with access to a
simplified Certificate of Analysis (CoA) for every cannabis product
available for sale on the Company's menu. The purpose of the new
protocol is to provide clients with secure knowledge that every
Aurora product available for purchase has been certified by an
independent third-party laboratory as having passed testing for the
widest possible range of potential contaminants.
The new system, developed in partnership with Anandia Labs Inc.
("Anandia"), Canada's foremost
cannabis genetics and testing laboratory, will provide a
certification link for each product featured on Aurora's menu, both
through the Company's website and through its one-of-a-kind mobile
application. Clicking the link will take clients to a
product-specific webpage, providing a simplified CoA indicating
that the product in question has been analyzed with high accuracy
for potency, and passed Anandia's rigorous testing procedures for
the presence of contaminants. These important enhancements will be
implemented in two steps. The first step, now complete, added these
certifications to the Company's website www.auroramj.com. The
second step, to be completed soon, will update Aurora's online shop
to place a certification link beside the image of each product for
sale.
"This initiative further extends Aurora's best-in-class Quality
Assurance and testing protocols, and gives our clients additional
certainty regarding the purity and safety of the cannabis we
produce and sell," said Terry Booth,
CEO. "From the founding of our Company, we have established and
emphasized a strict culture of regulatory compliance. We have never
used pesticides in our production, yet we have always tested all
the products we sell for the presence of pesticides and other
potential contaminants. It is imperative that patients have
confidence in the safety of the products they consume, and in the
integrity of the medical cannabis system. We believe our testing
disclosure process will raise the bar for the entire sector, and
offer a model for other companies to follow."
Aurora has used independent laboratories to test every lot of
product ever sold to clients for microbial contamination, as well
as any potential contamination by heavy metals and pesticides. In
October, 2016, the Company enhanced its procedures further by
shifting its testing to Anandia, which is able to test cannabis for
the presence of the broadest array of substances of any independent
commercial laboratory in Canada.
Since that time, Anandia has tested and passed 45 lots of Aurora
products.
"Aurora's initiative to provide access to quality control test
results will help their clients select the appropriate medication
and give them peace of mind that it does not contain pesticides or
other contaminants," said Dr. Jonathan
Page, President and CEO of Anandia Labs. "Our industry
leading testing protocols analyze for the presence of 51 pesticides
and plant growth regulators, as well as other contaminants such as
bacteria and heavy metals. We fully support Aurora in their efforts
to bring a new level of transparency to the medical cannabis
industry."
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises
Inc., is a licensed producer of medical cannabis pursuant to Health
Canada's Access to Cannabis for Medical Purposes Regulations
(ACMPR). The Company operates a 55,200 square foot,
state-of-the-art production facility in Mountain View County,
Alberta, and is currently
constructing a second 800,000 square foot production facility,
known as "Aurora Sky", at the Edmonton International Airport. The Aurora Sky
project has secured advanced technology from the most renowned
design and construction suppliers in the
Netherlands. Aurora's common shares trade on the TSX-V under
the symbol "ACB".
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth
CEO
This news release contains certain "forward-looking
statements" within the meaning of such statements under applicable
securities law. Forward-looking statements are frequently
characterized by words such as "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed" and other similar words, or
statements that certain events or conditions "may" or "will" occur.
These statements are only predictions. Various assumptions were
used in drawing the conclusions or making the projections contained
in the forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. There is no
assurance that the Proposal will be completed on the terms or
within the timeframe contemplated in this news release or at
all. The Company is under no obligation, and expressly
disclaims any intention or obligation, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as expressly required by
applicable law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Aurora Cannabis Inc.